AVCT.L

Avacta Group Plc
Avacta Group PLC - Notice of Results
12th September 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8400D
Avacta Group PLC
12 September 2024
 

 

 

 

 

 

12 September 2024

Avacta Group plc

 

("Avacta" or the "Company")

 

Notice of Results

 

Investor Presentation via Investor Meet Company

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, will announce its unaudited interim results on 30 September 2024 for the six months ended 30 June 2024.

 

Christina Coughlin, MD, PhD, Avacta's CEO, will discuss the results and the Company's operational and clinical progress via the Investor Meet Company platform on 30 September 2024 at 11:00 BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 29 September 2024, 09:00 BST, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:

https://www.investormeetcompany.com/avacta-group-plc/register-investor.

 

Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.

 

The Company will also post its results presentation on its website at the following page: https://avacta.com/investors/documents-presentations.

 

-Ends-

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Christina Coughlin, Chief Executive Officer

Michael Vinegrad, Group Communications Director

 

Tel: +44 (0) 1904 21 7070

www.avacta.com

Peel Hunt (Nomad and Broker)

James Steel / Chris Golden / Patrick Birkholm

 

www.peelhunt.com

ICR Consilium

Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

avacta@consilium-comms.com

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.

 

Avacta Therapeutics: a clinical stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.

 

Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics.

 

Avacta has two proprietary platforms, pre|CISION™ and Affimer®.

 

The pre|CISION™ platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumours compared with healthy tissues. The pre|CISION™ platform harnesses this tumour specific protease to activate pre|CISION™ peptide drug conjugates and pre|CISION™ antibody/Affimer® drug conjugates in the tumour microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimised to deliver the best outcomes for patients.

 

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.

 

 

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORFLFLRAIILLIS]]>
TwitterFacebookLinkedIn